Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperinsulinemia - Overview
Hyperinsulinemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperinsulinemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperinsulinemia - Companies Involved in Therapeutics Development
AmideBio LLC
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
PegBio Co Ltd
Rezolute Inc
Seneb BioSciences Inc
Sosei Heptares
XERIS Pharmaceuticals Inc
Zealand Pharma AS
Hyperinsulinemia - Drug Profiles
ABG-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avexitide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-02481 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNB-2401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperinsulinemia - Dormant Projects
Hyperinsulinemia - Product Development Milestones
Featured News & Press Releases
Jun 10, 2020: rezolute receives Rare Pediatric Disease Desigtion for RZ358 phase 2b candidate for the treatment of congenital hyperinsulinism ebling eligibility for priority review voucher
Jun 01, 2020: Rezolute presents RZ358 clinical data-validated model of the pharmacokinetics and glycemic response in congenital hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
May 28, 2020: Rezolute to present clinical data for RZ358, lead candidate in phase 2b trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
Apr 23, 2020: U.S. FDA grants orphan drug desigtion to AmideBio’s glucagon alog for the treatment of congenital hyperinsulinism
Feb 10, 2020: Rezolute initiates Phase 2b clinical trial of lead candidate RZ358 in congenital hyperinsulinism
Jul 29, 2019: Crinetics Pharmaceuticals to receive fil award of SBIR grant from NIH for congenital hyperinsulinism
Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on its drug candidate ACTH Antagonist CRN-02481 at ENDO2019
Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism
Apr 09, 2018: Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
Mar 12, 2018: Crinetics Pharmaceuticals Announces Presentation on Hyperinsulinemia Drug Candidate at ENDO 2018
Feb 08, 2018: FDA Grants Orphan Drug Desigtion (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH)
Feb 05, 2018: Hanmi annouces FDA orphan drug desigtion for LAPSGlucagon Alog
Sep 06, 2017: Crinetics Pharmaceuticals awarded SBIR Grant to develop new therapeutics for congenital hyperinsulinism
Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Hyperinsulinemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Hyperinsulinemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hyperinsulinemia - Pipeline by AmideBio LLC, H1 2020
Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Hyperinsulinemia - Pipeline by PegBio Co Ltd, H1 2020
Hyperinsulinemia - Pipeline by Rezolute Inc, H1 2020
Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, H1 2020
Hyperinsulinemia - Pipeline by Sosei Heptares, H1 2020
Hyperinsulinemia - Pipeline by XERIS Pharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Zealand Pharma AS, H1 2020
Hyperinsulinemia - Dormant Projects, H1 2020